Annual Accounts Receivable
$114.30 M
+$12.70 M+12.50%
01 December 2023
Summary:
Myriad Genetics annual accounts receivable is currently $114.30 million, with the most recent change of +$12.70 million (+12.50%) on 01 December 2023. During the last 3 years, it has risen by +$24.80 million (+27.71%). MYGN annual accounts receivable is now -14.64% below its all-time high of $133.90 million, reached on 30 June 2019.MYGN Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$125.70 M
+$7.90 M+6.71%
01 September 2024
Summary:
Myriad Genetics quarterly accounts receivable is currently $125.70 million, with the most recent change of +$7.90 million (+6.71%) on 01 September 2024. Over the past year, it has increased by +$11.40 million (+9.97%). MYGN quarterly accounts receivable is now -11.85% below its all-time high of $142.60 million, reached on 31 March 2019.MYGN Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MYGN Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +10.0% |
| 3 y3 years | +27.7% | +34.3% |
| 5 y5 years | -14.6% | +7.4% |
MYGN Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +27.7% | at high | +37.7% |
| 5 y | 5 years | -14.6% | +67.8% | at high | +84.6% |
| alltime | all time | -14.6% | +3471.9% | -11.8% | +5494.1% |
Myriad Genetics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $125.70 M(+6.7%) |
| June 2024 | - | $117.80 M(-0.3%) |
| Mar 2024 | - | $118.10 M(+3.3%) |
| Dec 2023 | $114.30 M(+12.5%) | $114.30 M(-0.8%) |
| Sept 2023 | - | $115.20 M(+3.1%) |
| June 2023 | - | $111.70 M(-6.2%) |
| Mar 2023 | - | $119.10 M(+17.2%) |
| Dec 2022 | $101.60 M(+11.3%) | $101.60 M(-0.6%) |
| Sept 2022 | - | $102.20 M(-6.9%) |
| June 2022 | - | $109.80 M(+8.0%) |
| Mar 2022 | - | $101.70 M(+11.4%) |
| Dec 2021 | $91.30 M(+2.0%) | $91.30 M(-2.5%) |
| Sept 2021 | - | $93.60 M(-1.3%) |
| June 2021 | - | $94.80 M(+0.7%) |
| Mar 2021 | - | $94.10 M(+10.6%) |
| Dec 2020 | $89.50 M(+31.4%) | - |
| Sept 2020 | - | $85.10 M(+25.0%) |
| June 2020 | $68.10 M(-49.1%) | $68.10 M(-33.6%) |
| Mar 2020 | - | $102.50 M(-13.4%) |
| Dec 2019 | - | $118.30 M(+1.1%) |
| Sept 2019 | - | $117.00 M(-12.6%) |
| June 2019 | $133.90 M(+34.6%) | $133.90 M(-6.1%) |
| Mar 2019 | - | $142.60 M(+22.3%) |
| Dec 2018 | - | $116.60 M(-2.1%) |
| Sept 2018 | - | $119.10 M(+19.7%) |
| June 2018 | $99.50 M(+10.3%) | $99.50 M(-19.6%) |
| Mar 2018 | - | $123.70 M(+2.1%) |
| Dec 2017 | - | $121.10 M(+7.0%) |
| Sept 2017 | - | $113.20 M(+25.5%) |
| June 2017 | $90.20 M(-1.6%) | $90.20 M(-21.4%) |
| Mar 2017 | - | $114.80 M(+6.7%) |
| Dec 2016 | - | $107.60 M(+9.6%) |
| Sept 2016 | - | $98.20 M(+7.1%) |
| June 2016 | $91.70 M(+6.9%) | $91.70 M(+0.7%) |
| Mar 2016 | - | $91.10 M(+8.1%) |
| Dec 2015 | - | $84.30 M(+1.1%) |
| Sept 2015 | - | $83.40 M(-2.8%) |
| June 2015 | $85.80 M(+4.8%) | $85.80 M(-6.9%) |
| Mar 2015 | - | $92.19 M(+13.5%) |
| Dec 2014 | - | $81.22 M(+7.3%) |
| Sept 2014 | - | $75.72 M(-7.5%) |
| June 2014 | $81.90 M(-13.2%) | $81.90 M(-0.9%) |
| Mar 2014 | - | $82.68 M(-1.7%) |
| Dec 2013 | - | $84.14 M(-2.4%) |
| Sept 2013 | - | $86.22 M(-8.6%) |
| June 2013 | $94.33 M(+56.1%) | $94.33 M(+1.2%) |
| Mar 2013 | - | $93.17 M(+23.3%) |
| Dec 2012 | - | $75.56 M(+20.9%) |
| Sept 2012 | - | $62.50 M(+3.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2012 | $60.44 M(+20.2%) | $60.44 M(+18.6%) |
| Mar 2012 | - | $50.95 M(+18.5%) |
| Dec 2011 | - | $42.99 M(-4.1%) |
| Sept 2011 | - | $44.82 M(-10.8%) |
| June 2011 | $50.27 M(+5.2%) | $50.27 M(+8.3%) |
| Mar 2011 | - | $46.44 M(+15.9%) |
| Dec 2010 | - | $40.06 M(-8.6%) |
| Sept 2010 | - | $43.83 M(-8.3%) |
| June 2010 | $47.80 M(+7.1%) | $47.80 M(-0.7%) |
| Mar 2010 | - | $48.12 M(-1.3%) |
| Dec 2009 | - | $48.77 M(+11.5%) |
| Sept 2009 | - | $43.74 M(-2.0%) |
| June 2009 | $44.62 M(+9.7%) | $44.62 M(-6.0%) |
| Mar 2009 | - | $47.47 M(+14.6%) |
| Dec 2008 | - | $41.43 M(-11.7%) |
| Sept 2008 | - | $46.93 M(+15.4%) |
| June 2008 | $40.66 M(+30.7%) | $40.66 M(+2.4%) |
| Mar 2008 | - | $39.70 M(+3.2%) |
| Dec 2007 | - | $38.47 M(+14.9%) |
| Sept 2007 | - | $33.49 M(+7.7%) |
| June 2007 | $31.10 M(+49.4%) | $31.10 M(+22.2%) |
| Mar 2007 | - | $25.46 M(+6.1%) |
| Dec 2006 | - | $24.01 M(+3.6%) |
| Sept 2006 | - | $23.16 M(+11.2%) |
| June 2006 | $20.82 M(+20.8%) | $20.82 M(+1.5%) |
| Mar 2006 | - | $20.51 M(+8.1%) |
| Dec 2005 | - | $18.98 M(+1.2%) |
| Sept 2005 | - | $18.75 M(+8.8%) |
| June 2005 | $17.24 M(+23.2%) | $17.24 M(+6.6%) |
| Mar 2005 | - | $16.17 M(-6.4%) |
| Dec 2004 | - | $17.28 M(+3.9%) |
| Sept 2004 | - | $16.63 M(+18.8%) |
| June 2004 | $13.99 M(+8.3%) | $13.99 M(-5.5%) |
| Mar 2004 | - | $14.82 M(+12.3%) |
| Dec 2003 | - | $13.19 M(+6.6%) |
| Sept 2003 | - | $12.37 M(-4.2%) |
| June 2003 | $12.92 M(+78.6%) | $12.92 M(+10.3%) |
| Mar 2003 | - | $11.71 M(+25.3%) |
| Dec 2002 | - | $9.34 M(+7.3%) |
| Sept 2002 | - | $8.70 M(+20.3%) |
| June 2002 | $7.23 M(+99.0%) | $7.23 M(+1.1%) |
| Mar 2002 | - | $7.15 M(+44.0%) |
| Dec 2001 | - | $4.97 M(+34.9%) |
| Sept 2001 | - | $3.68 M(+1.3%) |
| June 2001 | $3.63 M(+13.6%) | $3.63 M(+3.7%) |
| Mar 2001 | - | $3.51 M(-6.9%) |
| Dec 2000 | - | $3.77 M(+15.4%) |
| Sept 2000 | - | $3.26 M(+45.2%) |
| Mar 2000 | - | $2.25 M(-29.8%) |
| June 1999 | $3.20 M | $3.20 M |
FAQ
- What is Myriad Genetics annual accounts receivable?
- What is the all time high annual accounts receivable for Myriad Genetics?
- What is Myriad Genetics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Myriad Genetics?
- What is Myriad Genetics quarterly accounts receivable year-on-year change?
What is Myriad Genetics annual accounts receivable?
The current annual accounts receivable of MYGN is $114.30 M
What is the all time high annual accounts receivable for Myriad Genetics?
Myriad Genetics all-time high annual accounts receivable is $133.90 M
What is Myriad Genetics quarterly accounts receivable?
The current quarterly accounts receivable of MYGN is $125.70 M
What is the all time high quarterly accounts receivable for Myriad Genetics?
Myriad Genetics all-time high quarterly accounts receivable is $142.60 M
What is Myriad Genetics quarterly accounts receivable year-on-year change?
Over the past year, MYGN quarterly accounts receivable has changed by +$11.40 M (+9.97%)